<?xml version='1.0' encoding='utf-8'?>
<document id="25587128"><sentence text="Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design." /><sentence text="Breast cancer resistance protein (BCRP; ABCG2) limits intestinal absorption of low-permeability substrate drugs and mediates biliary excretion of drugs and metabolites" /><sentence text=" Based on clinical evidence of BCRP-mediated drug-drug interactions (DDIs) and the c" /><sentence text="421C&gt;A functional polymorphism affecting drug efficacy and safety, both the US Food and Drug Administration and European Medicines Agency recommend preclinical evaluation and, when appropriate, clinical assessment of BCRP-mediated DDIs" /><sentence text=" Although many BCRP substrates and inhibitors have been identified in vitro, clinical translation has been confounded by overlap with other transporters and metabolic enzymes" /><sentence text=" Regulatory recommendations for BCRP-mediated clinical DDI studies are challenging, as consensus is lacking on the choice of the most robust and specific human BCRP substrates and inhibitors and optimal study design" /><sentence text=" This review proposes a path forward based on a comprehensive analysis of available data" /><sentence text=" Oral sulfasalazine (1000 mg, immediate-release tablet) is the best available clinical substrate for intestinal BCRP, oral rosuvastatin (20 mg) for both intestinal and hepatic BCRP, and intravenous rosuvastatin (4 mg) for hepatic BCRP"><entity charOffset="6-19" id="DDI-PubMed.25587128.s8.e0" text="sulfasalazine" /><entity charOffset="123-135" id="DDI-PubMed.25587128.s8.e1" text="rosuvastatin" /><entity charOffset="198-210" id="DDI-PubMed.25587128.s8.e2" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.25587128.s8.e0" e2="DDI-PubMed.25587128.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25587128.s8.e0" e2="DDI-PubMed.25587128.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25587128.s8.e0" e2="DDI-PubMed.25587128.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25587128.s8.e1" e2="DDI-PubMed.25587128.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25587128.s8.e1" e2="DDI-PubMed.25587128.s8.e2" /></sentence><sentence text=" Oral curcumin (2000 mg) and lapatinib (250 mg) are the best available clinical BCRP inhibitors"><entity charOffset="6-14" id="DDI-PubMed.25587128.s9.e0" text="curcumin" /><entity charOffset="29-38" id="DDI-PubMed.25587128.s9.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.25587128.s9.e0" e2="DDI-PubMed.25587128.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25587128.s9.e0" e2="DDI-PubMed.25587128.s9.e1" /></sentence><sentence text=" To interrogate the worst-case clinical BCRP DDI scenario, study subjects harboring the BCRP c" /><sentence text="421C/C reference genotype are recommended" /><sentence text=" In addition, if sulfasalazine is selected as the substrate, subjects having the rapid acetylator phenotype are recommended"><entity charOffset="17-30" id="DDI-PubMed.25587128.s12.e0" text="sulfasalazine" /></sentence><sentence text=" In the case of rosuvastatin, subjects with the organic anion-transporting polypeptide 1B1 c"><entity charOffset="16-28" id="DDI-PubMed.25587128.s13.e0" text="rosuvastatin" /></sentence><sentence text="521T/T genotype are recommended, together with monitoring of rosuvastatin's cholesterol-lowering effect at baseline and DDI phase"><entity charOffset="76-87" id="DDI-PubMed.25587128.s14.e0" text="cholesterol" /></sentence><sentence text=" A proof-of-concept clinical study is being planned by a collaborative consortium to evaluate the proposed BCRP DDI study design" /><sentence text=" " /></document>